Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity

Science

Volumn 283, Issue 5400, 1999, Pages 397-401

  Gainetdinov, Raul R ^a   Wetsel, William C ^a   Jones, Sara R ^a   Levin, Edward D ^a   Jaber, Mohamed ^a,b   Caron, Marc C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMPHETAMINE; COCAINE; DOPAMINE TRANSPORTER; FLUOXETINE; METHYLPHENIDATE; NISOXETINE; NORADRENALIN; SEROTONIN; TRYPTOPHAN;

ARTICLE; ATTENTION DEFICIT DISORDER; COGNITION; DOPAMINE RELEASE; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN TISSUE; LOCOMOTION; NEUROTRANSMISSION; PRIORITY JOURNAL; SEROTONIN RELEASE;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR, ANIMAL; CARRIER PROTEINS; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FLUOXETINE; HUMANS; HYPERKINESIS; MAZE LEARNING; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SYMPORTERS; SYNAPTIC TRANSMISSION;

EID: 0033555898     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.283.5400.397     Document Type: Article

References (74)

1. A. Carlsson, in Psychopharmacology: The Third Generation of Progress. H. Y. Meltzer, Ed. (Raven, New York, 1987), pp. 39-48.
2. S. R. Jones et al., Proc. Natl. Acad. Sci. U.S.A. 95, 4029 (1998); R. R. Gainetdinov, S. R. Jones, F. Fumagalli, R. M. Wightman, M. G. Caron, Brain Res. Rev. 26, 148 (1998).
3. S. R. Jones et al., Proc. Natl. Acad. Sci. U.S.A. 95, 4029 (1998); R. R. Gainetdinov, S. R. Jones, F. Fumagalli, R. M. Wightman, M. G. Caron, Brain Res. Rev. 26, 148 (1998).
4. S. G. Amara and M. J. Kuhar, Annu. Rev. Neurosci. 16, 73 (1993); B. Giros and M. G. Caron, Trends Pharmacol. Sci. 14, 43 (1993); M. E. A. Reith, Ed., Neurotransmitter Transporters: Structure, Function and Regulation (Humana, Totowa, NJ, 1997).
5. S. G. Amara and M. J. Kuhar, Annu. Rev. Neurosci. 16, 73 (1993); B. Giros and M. G. Caron, Trends Pharmacol. Sci. 14, 43 (1993); M. E. A. Reith, Ed., Neurotransmitter Transporters: Structure, Function and Regulation (Humana, Totowa, NJ, 1997).
6. S. G. Amara and M. J. Kuhar, Annu. Rev. Neurosci. 16, 73 (1993); B. Giros and M. G. Caron, Trends Pharmacol. Sci. 14, 43 (1993); M. E. A. Reith, Ed., Neurotransmitter Transporters: Structure, Function and Regulation (Humana, Totowa, NJ, 1997).
7. B. Giros, M. Jaber, S. R. Jones, R. M. Wightman, M. G. Caron, Nature 379, 606 (1996).
8. R. Bosse et al., Neuron 19, 127 (1997); R. R. Gainetdinov, F. Fumagalli, S. R. Jones, M. G. Caron, J. Neurochem. 69, 1322 (1997); S. R. Jones, R. R. Gainetdinov, R. M. Wightman, M. G. Caron, J. Neurosci. 18, 1979 (1998); F. Fumagalli, R. R. Gainetdinov, K. J. Valenzano, M. G. Caron, ibid. 18, 4861 (1998); B. A. Rocha et al., Nature Neurosci. 1, 132 (1998); I. Sora et al., Proc. Natl. Acad. Sci. U.S.A. 95, 7699 (1998).
9. R. Bosse et al., Neuron 19, 127 (1997); R. R. Gainetdinov, F. Fumagalli, S. R. Jones, M. G. Caron, J. Neurochem. 69, 1322 (1997); S. R. Jones, R. R. Gainetdinov, R. M. Wightman, M. G. Caron, J. Neurosci. 18, 1979 (1998); F. Fumagalli, R. R. Gainetdinov, K. J. Valenzano, M. G. Caron, ibid. 18, 4861 (1998); B. A. Rocha et al., Nature Neurosci. 1, 132 (1998); I. Sora et al., Proc. Natl. Acad. Sci. U.S.A. 95, 7699 (1998).
10. R. Bosse et al., Neuron 19, 127 (1997); R. R. Gainetdinov, F. Fumagalli, S. R. Jones, M. G. Caron, J. Neurochem. 69, 1322 (1997); S. R. Jones, R. R. Gainetdinov, R. M. Wightman, M. G. Caron, J. Neurosci. 18, 1979 (1998); F. Fumagalli, R. R. Gainetdinov, K. J. Valenzano, M. G. Caron, ibid. 18, 4861 (1998); B. A. Rocha et al., Nature Neurosci. 1, 132 (1998); I. Sora et al., Proc. Natl. Acad. Sci. U.S.A. 95, 7699 (1998).
11. R. Bosse et al., Neuron 19, 127 (1997); R. R. Gainetdinov, F. Fumagalli, S. R. Jones, M. G. Caron, J. Neurochem. 69, 1322 (1997); S. R. Jones, R. R. Gainetdinov, R. M. Wightman, M. G. Caron, J. Neurosci. 18, 1979 (1998); F. Fumagalli, R. R. Gainetdinov, K. J. Valenzano, M. G. Caron, ibid. 18, 4861 (1998); B. A. Rocha et al., Nature Neurosci. 1, 132 (1998); I. Sora et al., Proc. Natl. Acad. Sci. U.S.A. 95, 7699 (1998).
12. R. Bosse et al., Neuron 19, 127 (1997); R. R. Gainetdinov, F. Fumagalli, S. R. Jones, M. G. Caron, J. Neurochem. 69, 1322 (1997); S. R. Jones, R. R. Gainetdinov, R. M. Wightman, M. G. Caron, J. Neurosci. 18, 1979 (1998); F. Fumagalli, R. R. Gainetdinov, K. J. Valenzano, M. G. Caron, ibid. 18, 4861 (1998); B. A. Rocha et al., Nature Neurosci. 1, 132 (1998); I. Sora et al., Proc. Natl. Acad. Sci. U.S.A. 95, 7699 (1998).
13. R. Bosse et al., Neuron 19, 127 (1997); R. R. Gainetdinov, F. Fumagalli, S. R. Jones, M. G. Caron, J. Neurochem. 69, 1322 (1997); S. R. Jones, R. R. Gainetdinov, R. M. Wightman, M. G. Caron, J. Neurosci. 18, 1979 (1998); F. Fumagalli, R. R. Gainetdinov, K. J. Valenzano, M. G. Caron, ibid. 18, 4861 (1998); B. A. Rocha et al., Nature Neurosci. 1, 132 (1998); I. Sora et al., Proc. Natl. Acad. Sci. U.S.A. 95, 7699 (1998).
14. E. H. Cook et al., Am. J. Hum. Genet. 56, 993 (1995); M. Gill, G. Daly, S. Heron, Z. Hawi, M. Fitzgerald, Mol. Psychiatry 2, 311 (1997).
15. E. H. Cook et al., Am. J. Hum. Genet. 56, 993 (1995); M. Gill, G. Daly, S. Heron, Z. Hawi, M. Fitzgerald, Mol. Psychiatry 2, 311 (1997).
16. Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association, Washington, DC, ed. 4, 1994).
17. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines (World Health Organization, Geneva, rev. 10, 1992); J. M. Swanson, Curr. Opin. Psychiatry 10, 300 (1996); J. Swanson, F. X. Castellanos, M. Murias, G. LaHoste, J. Kennedy, Curr. Opin Neurobiol. 8, 263 (1998).
18. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines (World Health Organization, Geneva, rev. 10, 1992); J. M. Swanson, Curr. Opin. Psychiatry 10, 300 (1996); J. Swanson, F. X. Castellanos, M. Murias, G. LaHoste, J. Kennedy, Curr. Opin Neurobiol. 8, 263 (1998).
19. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines (World Health Organization, Geneva, rev. 10, 1992); J. M. Swanson, Curr. Opin. Psychiatry 10, 300 (1996); J. Swanson, F. X. Castellanos, M. Murias, G. LaHoste, J. Kennedy, Curr. Opin Neurobiol. 8, 263 (1998).
20. R. A. Barkley, Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment (Guiford, New York, 1990); L. J. Hechtman, J. Psychiatry Neurosci. 19, 193 (1994); K. J. Gingerich, P. Turnock, J. K. Litfin, L. A. Roser, J. Clin. Psychol. 54, 415 (1998).
21. R. A. Barkley, Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment (Guiford, New York, 1990); L. J. Hechtman, J. Psychiatry Neurosci. 19, 193 (1994); K. J. Gingerich, P. Turnock, J. K. Litfin, L. A. Roser, J. Clin. Psychol. 54, 415 (1998).
22. R. A. Barkley, Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment (Guiford, New York, 1990); L. J. Hechtman, J. Psychiatry Neurosci. 19, 193 (1994); K. J. Gingerich, P. Turnock, J. K. Litfin, L. A. Roser, J. Clin. Psychol. 54, 415 (1998).
23. C. Bradley, Am. J. Psychiatry 94, 577 (1937); L. L. Greenhill, Pediatr. Psychopharmacol. 15, 1 (1992); C. W. Popper, J. Clin. Psychiatry 58, 14 (1997); M. Hornig, ibid. 59, 69 (1998).
24. C. Bradley, Am. J. Psychiatry 94, 577 (1937); L. L. Greenhill, Pediatr. Psychopharmacol. 15, 1 (1992); C. W. Popper, J. Clin. Psychiatry 58, 14 (1997); M. Hornig, ibid. 59, 69 (1998).
25. C. Bradley, Am. J. Psychiatry 94, 577 (1937); L. L. Greenhill, Pediatr. Psychopharmacol. 15, 1 (1992); C. W. Popper, J. Clin. Psychiatry 58, 14 (1997); M. Hornig, ibid. 59, 69 (1998).
26. C. Bradley, Am. J. Psychiatry 94, 577 (1937); L. L. Greenhill, Pediatr. Psychopharmacol. 15, 1 (1992); C. W. Popper, J. Clin. Psychiatry 58, 14 (1997); M. Hornig, ibid. 59, 69 (1998).
27. D. Taylor and B. T. Ho, Res. Commun. Chem. Pathol. Pharmacol. 21, 67 (1978); M. C. Ritz, E. J. Cone, M. J. Kuhar, Life Sci. 46, 635 (1990); L. S. Seiden, K. E. Sabol, G. A. Ricaurte, Annu. Rev. Pharmacol. Toxicol. 33, 639 (1993); R. Kuczenski and D. S. Segal, J. Neurochem. 68, 2032 (1997).
28. D. Taylor and B. T. Ho, Res. Commun. Chem. Pathol. Pharmacol. 21, 67 (1978); M. C. Ritz, E. J. Cone, M. J. Kuhar, Life Sci. 46, 635 (1990); L. S. Seiden, K. E. Sabol, G. A. Ricaurte, Annu. Rev. Pharmacol. Toxicol. 33, 639 (1993); R. Kuczenski and D. S. Segal, J. Neurochem. 68, 2032 (1997).
29. D. Taylor and B. T. Ho, Res. Commun. Chem. Pathol. Pharmacol. 21, 67 (1978); M. C. Ritz, E. J. Cone, M. J. Kuhar, Life Sci. 46, 635 (1990); L. S. Seiden, K. E. Sabol, G. A. Ricaurte, Annu. Rev. Pharmacol. Toxicol. 33, 639 (1993); R. Kuczenski and D. S. Segal, J. Neurochem. 68, 2032 (1997).
30. D. Taylor and B. T. Ho, Res. Commun. Chem. Pathol. Pharmacol. 21, 67 (1978); M. C. Ritz, E. J. Cone, M. J. Kuhar, Life Sci. 46, 635 (1990); L. S. Seiden, K. E. Sabol, G. A. Ricaurte, Annu. Rev. Pharmacol. Toxicol. 33, 639 (1993); R. Kuczenski and D. S. Segal, J. Neurochem. 68, 2032 (1997).
31. S. H. Snyder and J. L. Meyerhoff, Ann. N.Y. Acad. Sci. 205, 310 (1973).
32. All experiments were conducted in accordance with NIH guidelines for the care and use of animals and with an approved animal protocol from the Duke University Animal Care and Use Committee. Wildtype and homozygous DAT-KO mice were derived from crossing (over seven to eight generations) heterozygous DAT C57BL6/129SvJ animals. Mice were housed four or five to a cage, maintained under standard lab conditions (12-hour light/dark cycle) with food and water provided ad libitum, and tested at 12 to 15 weeks of age. Locomotion was evaluated in an automated Omnitech Digiscan apparatus (AccuScan Instruments, Columbus, OH) under illuminated conditions. Animals were observed individually at 5-min intervals for a maximum of 4 hours. Locomotor activity was measured in terms of the total distance covered (horizontal activity), rearings were expressed in terms of the number of vertical beam breaks (vertical activity), and the stereotypy time refers to the total time that stereotypic behaviors (repetitive beam breaks of a given beam or beams with intervals less than 1 s) were observed. In the "home" cage condition, mice were housed individually in cages for 24 hours, and then the cage and mouse were placed in the Omnitech Digiscan apparatus and activity was monitored over 1 hour. The data are expressed as the total distance covered in 1 hour for the novel and home cage environments. For drug studies, mice were initially placed into the open field for 30 min, then injected with saline (10 ml/kg, ip) or the drug, and returned to the open-field apparatus. All data are presented as means and SEMs. Statistical significance of all data presented in this paper was analyzed by two-way analysis of variance followed by Duncan's tests. A P < 0.05 was considered significant.
33. R. R. Gainetdinov, unpublished data.
34. Microdialysate samples were collected from the right striatum 24 hours after surgery, separated, and quantitated by high-performance liquid chromatography as described earlier for freely moving mice (2, 5). In accordance with previous reports (2, 5), basal extracellular DA concentrations in the DAT-KO mice were higher than those in the wild-type controls: Concentrations of DA in diatysates were 57.3 ± 13.4 fmol/ 20 μl in the wild-type mice (n = 12) and 354.5 ± 45.9 fmol/20 μl in the DAT-KO mice (n = 15). The data are presented as means and SEMs of the percentage of change from baseline (100%) from a mean of three samples from each mouse before exposure to the novel environment or before drug or saline administration.
35. All assessments of learning and memory processes were conducted in an eight-arm radial maze [E. D. Levin et al., Environ. Health Perspect. 105, 1320 (1997)]. The mice were food-deprived for about 5 hours before testing, and they were tested daily for 21 sessions with a win-shift paradigm. Before a given session, each of the eight arms was baited with slightly less than one-eighth of a piece of Fruit Loops breakfast cereal. At the start of each session, the mouse was placed into a cylinder in the center of the maze. After 10 s, the cylinder was removed and the mouse had full access to all arms of the maze. Only one entry in each arm was reinforced. The session continued until the mouse had entered all eight arms or 300 s had elapsed. Performance was assessed in terms of the numbers of arms entered (out of eight) before making an error (repeating an entry); these data were expressed as the entries to repeat. In addition, the numbers of perseverative errors were calculated. These errors refer to the tendency of a mouse to leave one arm and enter the arm where it had just been previously. Activity in the maze was also measured and expressed in terms of latency (total time in the maze divided by the total number of entries).
36. W. C. Wetsel, unpublished data.
37. H. F. Harlow and P. Settlage, Res. Publ. Assoc. Nerv. Ment. Dis. 27, 446 (1948); L. Kokkinidis and H. Anisman, Psychol. Bull. 88, 551 (1980); D. C. Rice, Neurotoxicology 14, 167 (1993); R. M. Ridley, Prog. Neurobiol. 44, 221 (1994); P. Collins, A. C. Roberts, R. Dias, B. J. Everitt, T. W. Robbins, J. Cognitive Neurosci. 10, 332 (1998).
38. H. F. Harlow and P. Settlage, Res. Publ. Assoc. Nerv. Ment. Dis. 27, 446 (1948); L. Kokkinidis and H. Anisman, Psychol. Bull. 88, 551 (1980); D. C. Rice, Neurotoxicology 14, 167 (1993); R. M. Ridley, Prog. Neurobiol. 44, 221 (1994); P. Collins, A. C. Roberts, R. Dias, B. J. Everitt, T. W. Robbins, J. Cognitive Neurosci. 10, 332 (1998).
39. H. F. Harlow and P. Settlage, Res. Publ. Assoc. Nerv. Ment. Dis. 27, 446 (1948); L. Kokkinidis and H. Anisman, Psychol. Bull. 88, 551 (1980); D. C. Rice, Neurotoxicology 14, 167 (1993); R. M. Ridley, Prog. Neurobiol. 44, 221 (1994); P. Collins, A. C. Roberts, R. Dias, B. J. Everitt, T. W. Robbins, J. Cognitive Neurosci. 10, 332 (1998).
40. H. F. Harlow and P. Settlage, Res. Publ. Assoc. Nerv. Ment. Dis. 27, 446 (1948); L. Kokkinidis and H. Anisman, Psychol. Bull. 88, 551 (1980); D. C. Rice, Neurotoxicology 14, 167 (1993); R. M. Ridley, Prog. Neurobiol. 44, 221 (1994); P. Collins, A. C. Roberts, R. Dias, B. J. Everitt, T. W. Robbins, J. Cognitive Neurosci. 10, 332 (1998).
41. H. F. Harlow and P. Settlage, Res. Publ. Assoc. Nerv. Ment. Dis. 27, 446 (1948); L. Kokkinidis and H. Anisman, Psychol. Bull. 88, 551 (1980); D. C. Rice, Neurotoxicology 14, 167 (1993); R. M. Ridley, Prog. Neurobiol. 44, 221 (1994); P. Collins, A. C. Roberts, R. Dias, B. J. Everitt, T. W. Robbins, J. Cognitive Neurosci. 10, 332 (1998).
42. In a previous study (4), it was reported that amphetamine and cocaine did not produce robust changes in activity in the DAT-KO mice. These drug effects were evaluated 2 hours after exposure to the novel environment when the hyperactive phenotype of these mice was less evident. By comparison, in the present study, we administered the drug 30 min after exposure to the novel environment when hyperactivity was at its peak, thereby enhancing our ability to discriminate an effect.
43. K. M. Taylor and S. H. Snyder, Brain Res. 28, 295 (1971); T. W. Robbins and B. J. Sahakian, Neuropharmacology 18, 931 (1979).
44. K. M. Taylor and S. H. Snyder, Brain Res. 28, 295 (1971); T. W. Robbins and B. J. Sahakian, Neuropharmacology 18, 931 (1979).
45. S. M. Tejani-Butt, J. Pharmacol. Exp. Ther. 260, 427 (1992).
46. J. D. Fernstrom and R. J. Wurtman, Science 173, 149 (1971); A. Tagliamonte, G. Biggio, L. Vargiu, G. L. Gessa, Life Sci. 12, 277 (1973); H. Lehnert and R. J. Wurtman, Psychother. Psychosom. 60, 18 (1993); S. N. Young, Neurosci. Biobehav. Rev. 20, 313 (1996); B. H. C. Westerink and J. B. DeVries, J. Neurochem. 56, 228 (1991).
47. J. D. Fernstrom and R. J. Wurtman, Science 173, 149 (1971); A. Tagliamonte, G. Biggio, L. Vargiu, G. L. Gessa, Life Sci. 12, 277 (1973); H. Lehnert and R. J. Wurtman, Psychother. Psychosom. 60, 18 (1993); S. N. Young, Neurosci. Biobehav. Rev. 20, 313 (1996); B. H. C. Westerink and J. B. DeVries, J. Neurochem. 56, 228 (1991).
48. J. D. Fernstrom and R. J. Wurtman, Science 173, 149 (1971); A. Tagliamonte, G. Biggio, L. Vargiu, G. L. Gessa, Life Sci. 12, 277 (1973); H. Lehnert and R. J. Wurtman, Psychother. Psychosom. 60, 18 (1993); S. N. Young, Neurosci. Biobehav. Rev. 20, 313 (1996); B. H. C. Westerink and J. B. DeVries, J. Neurochem. 56, 228 (1991).
49. J. D. Fernstrom and R. J. Wurtman, Science 173, 149 (1971); A. Tagliamonte, G. Biggio, L. Vargiu, G. L. Gessa, Life Sci. 12, 277 (1973); H. Lehnert and R. J. Wurtman, Psychother. Psychosom. 60, 18 (1993); S. N. Young, Neurosci. Biobehav. Rev. 20, 313 (1996); B. H. C. Westerink and J. B. DeVries, J. Neurochem. 56, 228 (1991).
50. J. D. Fernstrom and R. J. Wurtman, Science 173, 149 (1971); A. Tagliamonte, G. Biggio, L. Vargiu, G. L. Gessa, Life Sci. 12, 277 (1973); H. Lehnert and R. J. Wurtman, Psychother. Psychosom. 60, 18 (1993); S. N. Young, Neurosci. Biobehav. Rev. 20, 313 (1996); B. H. C. Westerink and J. B. DeVries, J. Neurochem. 56, 228 (1991).
51. P. S. Jensen et al., J. Am. Acad. Child. Adolesc. Psychiatry 36, 1672 (1997).
52. R. A. Barkley, Psychol. Bull. 121, 65 (1997).
53. In additional experiments, the DAT-KO mice were treated for three consecutive days with (±)-p-chlorophenylalanine (300 mg/kg, ip) to produce depletion of brain 5-HT concentrations by irreversible inhibition of tryptophan hydroxylase [H. Koyuncuoglu, L. Eroglu, M. Gungor, Psychopharmacologia 45, 163 (1975)]. Three days after the last injection, brain 5-HT concentrations decreased by about 65%. Under these conditions, the ability of methylphenidate (30 mg/kg, ip) to produce calming effects on the hyperactivity of DAT-KO mice was significantly attenuated (14).
54. L. Shuster, J. Hudson, M. Anton, D. Righi, Psychopharmacology 77, 31 (1982); S. L. Jaffe, J. Am. Acad. Child Adolesc. Psychiatry 30, 773 (1991); W. L. Woolverton and K. M. Johnson, Trends Pharmacol. Sci. 13, 193 (1992); L. S. Seiden and K. E. Sabol, in Handbook of Neurotoxicology, L. W. Chang, and R. S. Dyer, Eds. (Dekker, New York, 1995), pp. 825-843.
55. L. Shuster, J. Hudson, M. Anton, D. Righi, Psychopharmacology 77, 31 (1982); S. L. Jaffe, J. Am. Acad. Child Adolesc. Psychiatry 30, 773 (1991); W. L. Woolverton and K. M. Johnson, Trends Pharmacol. Sci. 13, 193 (1992); L. S. Seiden and K. E. Sabol, in Handbook of Neurotoxicology, L. W. Chang, and R. S. Dyer, Eds. (Dekker, New York, 1995), pp. 825-843.
56. L. Shuster, J. Hudson, M. Anton, D. Righi, Psychopharmacology 77, 31 (1982); S. L. Jaffe, J. Am. Acad. Child Adolesc. Psychiatry 30, 773 (1991); W. L. Woolverton and K. M. Johnson, Trends Pharmacol. Sci. 13, 193 (1992); L. S. Seiden and K. E. Sabol, in Handbook of Neurotoxicology, L. W. Chang, and R. S. Dyer, Eds. (Dekker, New York, 1995), pp. 825-843.
57. L. Shuster, J. Hudson, M. Anton, D. Righi, Psychopharmacology 77, 31 (1982); S. L. Jaffe, J. Am. Acad. Child Adolesc. Psychiatry 30, 773 (1991); W. L. Woolverton and K. M. Johnson, Trends Pharmacol. Sci. 13, 193 (1992); L. S. Seiden and K. E. Sabol, in Handbook of Neurotoxicology, L. W. Chang, and R. S. Dyer, Eds. (Dekker, New York, 1995), pp. 825-843.
58. B. B. Brodie and P. A. Shore, Ann. N.Y. Acad. Sci. 66, 631 (1957); M. A. Geyer, Behav. Brain Res. 73, 31 (1996); I. Lucki, Biol. Psychiatry 44, 151 (1998).
59. B. B. Brodie and P. A. Shore, Ann. N.Y. Acad. Sci. 66, 631 (1957); M. A. Geyer, Behav. Brain Res. 73, 31 (1996); I. Lucki, Biol. Psychiatry 44, 151 (1998).
60. B. B. Brodie and P. A. Shore, Ann. N.Y. Acad. Sci. 66, 631 (1957); M. A. Geyer, Behav. Brain Res. 73, 31 (1996); I. Lucki, Biol. Psychiatry 44, 151 (1998).
61. H. G. Baumgarten and Z. Grozdanovic, Pharmacopsychiatry 28, 73 (1995); D. G. LeMarquand et al., Neuropsychopharmacology 19, 333 (1998); T. W. Robbins et al., Ann. N.Y. Acad. Sci. 846, 222 (1998).
62. H. G. Baumgarten and Z. Grozdanovic, Pharmacopsychiatry 28, 73 (1995); D. G. LeMarquand et al., Neuropsychopharmacology 19, 333 (1998); T. W. Robbins et al., Ann. N.Y. Acad. Sci. 846, 222 (1998).
63. H. G. Baumgarten and Z. Grozdanovic, Pharmacopsychiatry 28, 73 (1995); D. G. LeMarquand et al., Neuropsychopharmacology 19, 333 (1998); T. W. Robbins et al., Ann. N.Y. Acad. Sci. 846, 222 (1998).
64. P. D. Mabry and B. A. Campbell, Brain Res. 49, 381 (1973); T. K. Green and J. A. Harvey, J. Pharmacol. Exp. Ther. 190, 109 (1974); D. A. Brase and H. H. Loh, Life Sci. 16, 1005 (1975); G. R. Breese, B. R. Cooper, A. S. Hollister, Psychopharmacologia 44, 5 (1975); A. S. Hollister, G. R. Breese, C. M. Kuhn, B. R. Cooper, S. M. Schanberg, J. Pharmacol. Exp. Ther. 198, 12 (1976); J. A. Milso and C. J. Pycock, Br. J. Pharmacol. 56, 77 (1976); T. G. Heffner and L. S. Seiden, Brain Res. 244, 81 (1982); R. M. Kostrzewa, R. Brus, J. H. Kalbfleisch, K. W. Perry, R. W. Fuller, Brain. Res. Bull. 34, 161 (1994).
65. P. D. Mabry and B. A. Campbell, Brain Res. 49, 381 (1973); T. K. Green and J. A. Harvey, J. Pharmacol. Exp. Ther. 190, 109 (1974); D. A. Brase and H. H. Loh, Life Sci. 16, 1005 (1975); G. R. Breese, B. R. Cooper, A. S. Hollister, Psychopharmacologia 44, 5 (1975); A. S. Hollister, G. R. Breese, C. M. Kuhn, B. R. Cooper, S. M. Schanberg, J. Pharmacol. Exp. Ther. 198, 12 (1976); J. A. Milso and C. J. Pycock, Br. J. Pharmacol. 56, 77 (1976); T. G. Heffner and L. S. Seiden, Brain Res. 244, 81 (1982); R. M. Kostrzewa, R. Brus, J. H. Kalbfleisch, K. W. Perry, R. W. Fuller, Brain. Res. Bull. 34, 161 (1994).
66. P. D. Mabry and B. A. Campbell, Brain Res. 49, 381 (1973); T. K. Green and J. A. Harvey, J. Pharmacol. Exp. Ther. 190, 109 (1974); D. A. Brase and H. H. Loh, Life Sci. 16, 1005 (1975); G. R. Breese, B. R. Cooper, A. S. Hollister, Psychopharmacologia 44, 5 (1975); A. S. Hollister, G. R. Breese, C. M. Kuhn, B. R. Cooper, S. M. Schanberg, J. Pharmacol. Exp. Ther. 198, 12 (1976); J. A. Milso and C. J. Pycock, Br. J. Pharmacol. 56, 77 (1976); T. G. Heffner and L. S. Seiden, Brain Res. 244, 81 (1982); R. M. Kostrzewa, R. Brus, J. H. Kalbfleisch, K. W. Perry, R. W. Fuller, Brain. Res. Bull. 34, 161 (1994).
67. P. D. Mabry and B. A. Campbell, Brain Res. 49, 381 (1973); T. K. Green and J. A. Harvey, J. Pharmacol. Exp. Ther. 190, 109 (1974); D. A. Brase and H. H. Loh, Life Sci. 16, 1005 (1975); G. R. Breese, B. R. Cooper, A. S. Hollister, Psychopharmacologia 44, 5 (1975); A. S. Hollister, G. R. Breese, C. M. Kuhn, B. R. Cooper, S. M. Schanberg, J. Pharmacol. Exp. Ther. 198, 12 (1976); J. A. Milso and C. J. Pycock, Br. J. Pharmacol. 56, 77 (1976); T. G. Heffner and L. S. Seiden, Brain Res. 244, 81 (1982); R. M. Kostrzewa, R. Brus, J. H. Kalbfleisch, K. W. Perry, R. W. Fuller, Brain. Res. Bull. 34, 161 (1994).
68. P. D. Mabry and B. A. Campbell, Brain Res. 49, 381 (1973); T. K. Green and J. A. Harvey, J. Pharmacol. Exp. Ther. 190, 109 (1974); D. A. Brase and H. H. Loh, Life Sci. 16, 1005 (1975); G. R. Breese, B. R. Cooper, A. S. Hollister, Psychopharmacologia 44, 5 (1975); A. S. Hollister, G. R. Breese, C. M. Kuhn, B. R. Cooper, S. M. Schanberg, J. Pharmacol. Exp. Ther. 198, 12 (1976); J. A. Milso and C. J. Pycock, Br. J. Pharmacol. 56, 77 (1976); T. G. Heffner and L. S. Seiden, Brain Res. 244, 81 (1982); R. M. Kostrzewa, R. Brus, J. H. Kalbfleisch, K. W. Perry, R. W. Fuller, Brain. Res. Bull. 34, 161 (1994).
69. P. D. Mabry and B. A. Campbell, Brain Res. 49, 381 (1973); T. K. Green and J. A. Harvey, J. Pharmacol. Exp. Ther. 190, 109 (1974); D. A. Brase and H. H. Loh, Life Sci. 16, 1005 (1975); G. R. Breese, B. R. Cooper, A. S. Hollister, Psychopharmacologia 44, 5 (1975); A. S. Hollister, G. R. Breese, C. M. Kuhn, B. R. Cooper, S. M. Schanberg, J. Pharmacol. Exp. Ther. 198, 12 (1976); J. A. Milso and C. J. Pycock, Br. J. Pharmacol. 56, 77 (1976); T. G. Heffner and L. S. Seiden, Brain Res. 244, 81 (1982); R. M. Kostrzewa, R. Brus, J. H. Kalbfleisch, K. W. Perry, R. W. Fuller, Brain. Res. Bull. 34, 161 (1994).
70. P. D. Mabry and B. A. Campbell, Brain Res. 49, 381 (1973); T. K. Green and J. A. Harvey, J. Pharmacol. Exp. Ther. 190, 109 (1974); D. A. Brase and H. H. Loh, Life Sci. 16, 1005 (1975); G. R. Breese, B. R. Cooper, A. S. Hollister, Psychopharmacologia 44, 5 (1975); A. S. Hollister, G. R. Breese, C. M. Kuhn, B. R. Cooper, S. M. Schanberg, J. Pharmacol. Exp. Ther. 198, 12 (1976); J. A. Milso and C. J. Pycock, Br. J. Pharmacol. 56, 77 (1976); T. G. Heffner and L. S. Seiden, Brain Res. 244, 81 (1982); R. M. Kostrzewa, R. Brus, J. H. Kalbfleisch, K. W. Perry, R. W. Fuller, Brain. Res. Bull. 34, 161 (1994).
71. P. D. Mabry and B. A. Campbell, Brain Res. 49, 381 (1973); T. K. Green and J. A. Harvey, J. Pharmacol. Exp. Ther. 190, 109 (1974); D. A. Brase and H. H. Loh, Life Sci. 16, 1005 (1975); G. R. Breese, B. R. Cooper, A. S. Hollister, Psychopharmacologia 44, 5 (1975); A. S. Hollister, G. R. Breese, C. M. Kuhn, B. R. Cooper, S. M. Schanberg, J. Pharmacol. Exp. Ther. 198, 12 (1976); J. A. Milso and C. J. Pycock, Br. J. Pharmacol. 56, 77 (1976); T. G. Heffner and L. S. Seiden, Brain Res. 244, 81 (1982); R. M. Kostrzewa, R. Brus, J. H. Kalbfleisch, K. W. Perry, R. W. Fuller, Brain. Res. Bull. 34, 161 (1994).
72. P. A. Broderick and C. F. Phelix, Neurosci. Biobehav. Rev. 21, 227 (1997); F. J. White, Nature 393, 118 (1998).
73. P. A. Broderick and C. F. Phelix, Neurosci. Biobehav. Rev. 21, 227 (1997); F. J. White, Nature 393, 118 (1998).
74. This work was supported in part by grant MH-40159 from NIH and unrestricted gifts from Bristol Myers Squibb and Zeneca Pharmaceutical (to M.G.C.). M.G.C. is an Investigator of the Howard Hughes Medical Institute. R.R.G. was a recipient of a fellowship from the Tourette Syndrome Association and is a visiting researcher from the Institute of Pharmacology, Russian Academy of Medical Sciences, Baltiyskaya 8, 125315 Moscow, Russia.